PDCD1 and melanoma: The clinical application of triplet therapies in the first-line metastatic setting has been limited by a lack of comparison to either single-agent anti-PD-1 or IPI + NIVO, which have since emerged as standards of care for both BRAF-mutant and wild-type melanoma.